斯佩索利马布治疗泛性性牛皮:对两项关键临床试验的综述,支持最初的美国监管批准
Eran C Gwillim1,2, Anna J Nichols1
1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Frontiers in immunology
|August 6, 2024
概括
斯佩索利马布通过准IL-36信号传递,有效地治疗泛性性牛皮 (GPP) 发作. 临床试验显示,GPP患者的皮肤快速清除和持续改善,提高生活质量.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泛性性牛皮 (GPP) 是一种罕见的,严重的炎症性皮肤疾病.
- IL-36通路的失调是GPP病变发生的核心.
- 向IL-36为GPP提供了一个治疗策略.
研究的目的:
- 审查针对GPP爆发的spesolimab临床试验数据.
- 评估spesolimab在GPP治疗中的疗效和安全性.
- 评估斯佩索利马布对患者生活质量的影响.
主要方法:
- 从第一阶段的概念验证试验 (NCT02978690) 的数据的审查.
- 在GPP发作患者中随机进行的EffisayilTM 1试验 (NCT03782792) 的分析.
- 评估GPPGA和GPPASI得分,以及不良事件.
主要成果:
- 在第一期和EffisayilTM 1试验中,spesolimab迅速改善了GPP症状.
- 随着spesolimab.观察到显著降低的发生和整体疾病严重程度.
- 与安慰剂相比,在spesolimab组中实现了较高的皮肤清除率.
结论:
- 斯佩索利马布在治疗GPP爆发时表现出显著的疗效和有利的安全性.
- 该药物提供了快速和持续的临床改善.
- 斯佩索利马布是一种有针对性的疗法,可以改善GPP患者的生活质量.
相关概念视频
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


